Global, regional and national burden of polycystic ovary syndrome: historical trends from 1990 to 2021 and projections to 2035 - Top-Institutions - MDSpire

Global, regional and national burden of polycystic ovary syndrome: historical trends from 1990 to 2021 and projections to 2035

  • By

  • Hu Li

  • Zhaoyi Jing

  • Rui Li

  • Zheng Shen

  • Tianyu Bai

  • Qingyu Song

  • April 1, 2026

  • 0 min

Share

Top Institutions in Obgyn

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Reproductive Medicine
    • Epidemiology

  • #2

    University of California, Los Angeles (UCLA) - David Geffen School of Medicine
    University of California, Los Angeles (UCLA) - David Geffen School of Medicine

    Los Angeles, CA

    Key Differentiators

    • Endocrinology
    • Obstetrics and Gynecology
    • Metabolic Research

  • #3

    Harvard Medical School - Massachusetts General Hospital
    Harvard Medical School - Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Reproductive Endocrinology
    • Women's Health

  • #4

    University of Oxford - Nuffield Department of Women's & Reproductive Health
    University of Oxford - Nuffield Department of Women's & Reproductive Health

    Oxford, Oxfordshire

    Key Differentiators

    • Reproductive Medicine
    • Endocrinology
    • Public Health

  • #5

    Monash University - Monash Centre for Health Research and Implementation
    Monash University - Monash Centre for Health Research and Implementation

    Melbourne, Victoria

    Key Differentiators

    • Endocrinology
    • Reproductive Health
    • Implementation Science

Original Source(s)

Global, regional and national burden of polycystic ovary syndrome: historical trends from 1990 to 2021 and projections to 2035

  • by Hu Li, Zhaoyi Jing, Rui Li, Zheng Shen, Tianyu Bai, Qingyu Song

  • April 1, 2026

Related Content

Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case–control study

Ovarian intelligence: AI applications leveraging AMH and inhibin B

Former FDA leaders, pharma speak out on mifepristone